GSK

Business Context and Reporting Period

Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Three months ended 31 March 2016 (Q1 2016)
Issuance Date: 27 April 2016

GSK reported strong first-quarter performance driven by new product sales, cost control, and restructuring benefits. The results reflect the post-Novartis transaction structure, comprising three core businesses: Pharmaceuticals (including HIV), Vaccines, and Consumer Healthcare. The Oncology business was disposed of in March 2015 and is excluded from current results.

Key Financial Metrics

Note: CER = Constant Exchange Rate. Total EPS decline is due to a £9.3bn profit from the Oncology disposal in Q1 2015.

Material Changes vs. Prior Period

• Revenue Growth: Group turnover increased 8% on a reported basis and 6% on a pro-forma basis.
  • Pharmaceuticals: Reported -1% (Pro-forma +5%). HIV sales surged 57% driven by Triumeq and Tivicay. Respiratory sales declined 2% due to Seretide/Advair patent erosion, partially offset by new Ellipta products.
  • Vaccines: Reported +23% (Pro-forma +14%). Growth driven by the Meningitis portfolio (Bexsero, Menveo) and CDC purchases in the US.
  • Consumer Healthcare: Reported +26% (Pro-forma +4%). Strong performance in Oral Health (Sensodyne) and Wellness (Flonase OTC, Voltaren).
• Profitability: Core operating profit grew 13% (CER) with margins expanding across all three businesses due to operating leverage and restructuring savings of £0.4bn in the quarter.
• Non-Core Items: Total results were significantly impacted by non-core charges of £836m in Q1 2016 (restructuring, transaction-related adjustments), compared to a net credit of £7.9bn in Q1 2015 (Oncology disposal gains).
• Balance Sheet: Net debt increased to £12.5bn from £10.7bn at year-end 2015, primarily due to dividend payments (£919m) and adverse foreign exchange impacts on USD-denominated debt.

Guidance, Outlook, and Risks

• 2016 Guidance: GSK raised its full-year 2016 core EPS growth guidance to 10-12% (CER), up from previous expectations.
• Dividends: Declared a Q1 interim dividend of 19p. Maintains expectation of an annual ordinary dividend of 80p for 2016 and 2017.
• Restructuring: The combined restructuring and integration programme remains on track to deliver £3bn in annual cost savings by the end of 2017.
• R&D Pipeline: New product sales reached £821m, representing 20% of total Pharmaceutical sales. The target of £6bn annual revenue from new products is now expected to be met by 2018 (two years ahead of schedule).
• Risks & Contingencies:
  • Legal: Aggregate provision for legal disputes is £0.3bn. Significant proceedings include product liability, IP, and anti-trust matters.
  • Regulatory: FDA placed a clinical hold on the CARDIO-TTR study for transthyretin amyloidosis following safety findings in a partner study.
  • Market Dynamics: Continued pricing pressure in Respiratory products and generic competition (e.g., Advair, Avodart) remain headwinds.

Investor Verification Checklist

• Pro-Forma Adjustments: Verify the impact of the Novartis transaction on comparability; reported growth includes full quarter of acquired businesses, while Q1 2015 was partial.
• Core vs. Total EPS: Distinguish between Core EPS (19.8p, +8%) and Total EPS (5.8p, -97%) to understand underlying operational performance versus one-off disposal gains/losses.
• Respiratory Transition: Monitor the offset between declining Seretide/Advair sales and growth in new Ellipta products (Relvar, Breo, Anoro, Incruse).
• Net Debt Trajectory: Assess the impact of dividend payments and FX fluctuations on the rising net debt position (£12.5bn).
• Restructuring Savings: Confirm delivery of the £3bn annual cost savings target by end-2017 to support margin expansion.